Fruquintinib: Completed Phase III enrollment

Chi-Med completed enrollment of 416 patients in the double-blind, placebo-controlled, Chinese Phase III FRESCO trial evaluating 5 mg oral fruquintinib once daily for the first 3 weeks of each 4-week c...